对症治疗与联合化疗治疗晚期非小细胞肺癌

目的 评价联合化疗对晚期非小细胞肺癌（ＮＳＣＬＣ）患者生存期的影响。方法 ７０例晚期非小细胞肺癌患者配对分组；３５例拒绝化疗者，接受对症治疗（对症组）。３５例接受联合化疗，丝裂霉素８￣１０ｍｇ／ｍ＾２，第１天，顺铂２０ｍｇ／ｍ＾２，第１￣５天，长春酰胺３ｍｇ／ｍ＾２，第１，８天，每４周重复，２￣４周期后，口服喃呋啶２００￣３００ｍｇ，每天３次，至肿瘤复发或进展止。结果 中位生存期化疗组为９个月，对

Symptomatic treatment versus combination chemotherapy in advanced non small cell lung cancer

OBJECTIVE: To evaluate the effects on survival of combination chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). METHODS: Seventy patients with advanced NSCLC were pairingly divided into two equal groups: 35 patients who refused chemotherapy received symptomatic treatment; the other 35 patients received combined chemotherapy with mitomycin(8-10 mg/m2, dl), vindesine (3 mg/m2, dl, 8) cisplatin (20 mg/m2, dl-5), repeated every four weeks for 2-4 cycles and followed by oral administration of Ftorafur (FT-207) 200-300 mg tid, until recurrence or progression of disease. RESULTS: The overall median survival time in the chemotherapy group was 9 months, and 4.5 months in the symptomatically treated group. The one-year survival rate was 34.3% and 8.0% respectively. The major toxic effects of chemotherapy were gastrointestinal tract reactions and myelosuppression. CONCLUSION: Combination chemotherapy can prolong survival time in patients with advanced NSCLC.